What Happened

Colossal Biosciences, the Dallas-based de-extinction startup, is reportedly in talks to raise new capital at a valuation between $20 billion and $30 billion, according to a report by Axios cited by TechCrunch on July 20, 2026. This would represent a 2x to 3x increase from the company's previous $10.2 billion valuation, set approximately 16 months ago.

Key details remain unconfirmed. It is not known who is leading the round, how much capital Colossal seeks to raise, or whether talks are at an advanced stage. The company did not respond to TechCrunch's request for comment. However, the report notes that Colossal has begun generating revenue over the past year — a meaningful milestone for a company whose flagship projects (woolly mammoth, dodo bird, dire wolf resurrection) remain years from ecological reintroduction.

Colossal has also spun out three startups from its core science: Breaking (plastic degradation), Form Bio (computational biology platform, $30M raised), and Astromech (AI-driven predictive modeling for biology, valued at $2 billion in March 2026). The UAE government invested $60 million in Colossal, according to Wired, and the company has offered its conservation technology to the U.S. government.

Why It Matters

A $20B–$30B valuation for a five-year-old company whose primary product — resurrected extinct animals — has not yet been delivered tells you that investors are pricing platform value, not project outcomes. Colossal is being valued like a biotech holding company: a parent entity that incubates, spins out, and retains equity in multiple commercially viable businesses.

This matters for the broader deep-tech funding environment. The signal aligns with a pattern visible across recent funding activity — Crusoe raising at $30B for AI data centers, Blue Origin seeking $10B in its first VC-led round, and Hadrian reportedly targeting $7.5B. Capital is flowing aggressively toward capital-intensive, science-heavy platforms with long horizons but multiple monetization paths.

For AI-specific operators, the Astromech spinout is the most relevant data point. An AI predictive modeling company focused on biology hitting a $2B standalone valuation confirms that the intersection of AI and life sciences commands premium multiples — even as a spinout from a company whose primary brand is associated with resurrecting prehistoric animals.

Who Is Affected

Deep-tech and biotech founders should study Colossal's spinout strategy as a template for monetizing platform science before the flagship use case matures. AI-for-biology startups should benchmark against Astromech's $2B valuation when raising capital. Investors in synthetic biology need to assess whether the 2x–3x valuation jump in 16 months is justified by revenue generation and spinout equity or reflects broader market froth in deep tech.

Strategic Implications

For AI startup founders: Colossal's spinout model — building core science, then extracting commercially viable applications into independently funded entities — is worth studying. If your platform serves multiple verticals, consider whether spinouts could unlock higher aggregate valuations than keeping everything under one roof.

For developers/operators building with AI APIs: Astromech's $2B valuation suggests that biology-specific AI tooling is an emerging category. If you work in life sciences or computational biology, watch for Astromech's API or platform offerings, which could provide specialized predictive modeling capabilities distinct from general-purpose LLMs.

For non-technical business owners evaluating AI tools: Colossal's artificial womb technology, expected to be ready next year per CEO Ben Lamm, could have applications in human fertility treatment. If you operate in healthcare or fertility services, this is a signal to monitor. More broadly, the funding boom in deep tech suggests that science-platform companies will increasingly produce commercial products across unexpected verticals.

What to Watch Next

Monitor for confirmation of the round's lead investor and total raise size, which will indicate whether this is a strategic round (government or sovereign wealth participation) or a traditional VC-led deal. Also watch for any IPO timeline signals, given the broader trend of high-valuation private companies eyeing public markets.

Frequently Asked Questions

Q: What is Colossal Biosciences' current valuation?

A: Colossal's last confirmed valuation was $10.2 billion. The company is reportedly in talks to raise at a $20B–$30B valuation, but this has not been confirmed by the company.

Q: How does Colossal Biosciences make money?

A: Colossal has three revenue streams: selling conservation technology to governments, spinning out startups (Breaking, Form Bio, Astromech), and eventually generating biodiversity credits if extinct species are reintroduced to native habitats. The company began generating revenue over the past year, though specific figures are not public.